The FDA Wants to Make Many Popular Prescription Drugs OTC—A Great Idea. Here’s Why It’s Unlikely to Happen

Key Takeaways

• Naloxone nasal spray went OTC in 2023, injectable still prescription
• OTC switches for Claritin and Prilosec cut patient out‑of‑pocket costs
• Albuterol inhalers are OTC abroad but prescription‑only in the U.S.
• Congress could invert evidentiary standards to presume OTC eligibility

Pulse Analysis

The FDA’s recent rhetoric, championed by Commissioner Marty Makary, frames over‑the‑counter (OTC) access as a consumer right rather than a regulatory hurdle. By moving drugs from prescription to OTC, the transaction shifts from insurance‑subsidized payments to cash purchases, which historically drives prices down. The article cites the dramatic price drops seen when loratadine, omeprazole, ibuprofen and naproxen entered the OTC market, illustrating how third‑party payers inflate costs through negotiated rebates and pharmacy‑benefit‑manager fees.

Despite clear market incentives, the FDA often waits for drug makers to request reclassification, a dynamic that benefits manufacturers by preserving a captive, high‑margin prescription market. The case of naloxone exemplifies this tension: the nasal spray achieved OTC status only after persistent FDA pressure, while the cheaper injectable form remains prescription‑only in the United States, even though it is freely available abroad. Similar inertia surrounds oral contraceptives, albuterol inhalers, and HIV pre‑exposure prophylaxis, all of which are OTC in many comparable jurisdictions.

Policy analysts propose legislative fixes to break this stalemate. Economist Sam Peltzman suggests flipping the evidentiary burden so that drugs with long‑standing safety records are presumed OTC unless the FDA can prove otherwise. Another proposal is international reciprocity, allowing U.S. sales of medicines already OTC in trusted regulators like Health Canada or the UK. Such reforms could accelerate price competition, expand patient choice, and diminish the regulatory capture that currently lets pharmaceutical firms profit from restricted access.